# TAF1L

## Overview
TAF1L is a gene that encodes the protein TATA-box binding protein associated factor 1 like, which is a crucial component of the transcription factor IID (TFIID) complex. This protein plays a significant role in transcription regulation by RNA polymerase II, particularly in male germ cells during spermatogenesis. TAF1L is a germ cell-specific paralog of the TFIID subunit TAF1 and is involved in chromatin remodeling and gene expression through its histone acetyltransferase activity. The protein's interactions with the TATA-binding protein and bromodomains are essential for its function in transcriptional regulation and chromatin interactions. TAF1L has been implicated in various cancers, including oral squamous cell carcinoma and gastric cancers, where its expression and mutations can influence tumorigenesis and cancer progression (Wang2020TAF1L; Oh2016Frameshift; WhiteCooper2011Unique).

## Function
TAF1L is a gene that encodes a protein involved in transcription regulation, specifically as part of the TFIID complex, which is crucial for the initiation of transcription by RNA polymerase II. In healthy human cells, TAF1L plays a significant role in transcription initiation, chromatin remodeling, and gene expression. It is active in the nucleus, where it interacts with other transcription factors to facilitate the transcription of specific genes (WhiteCooper2011Unique).

TAF1L is a germ cell-specific paralog of the TFIID subunit TAF1, and it is particularly important in male germ cells during spermatogenesis. It helps maintain high levels of transcription necessary for producing large amounts of mRNA for translation in haploid cells. This function is crucial for normal spermatogenesis, as it ensures elevated transcription levels even during meiotic sex chromosome inactivation (WhiteCooper2011Unique).

The protein's involvement in transcription regulation is also linked to its histone acetyltransferase activity, which contributes to chromatin remodeling, a process essential for gene expression and cellular differentiation (Wang2020TAF1L). These molecular activities underscore TAF1L's role in maintaining proper cellular function and development.

## Clinical Significance
TAF1L has been implicated in various cancers and other conditions due to mutations and alterations in its expression. In oral squamous cell carcinoma (OSCC), TAF1L is overexpressed, promoting cancer progression by decreasing autophagy-dependent apoptosis. This overexpression is associated with increased cell proliferation, migration, and invasion, suggesting its role as an oncogene in OSCC (Wang2020TAF1L). In gastric and colorectal cancers, particularly those with high microsatellite instability (MSI-H), frameshift mutations in TAF1L have been identified. These mutations result in premature stop codons, leading to a loss-of-function effect, which may contribute to tumorigenesis (Oh2016Frameshift).

TAF1L mutations have also been observed in pulmonary carcinoid tumors, where they are part of a broader pattern of genomic alterations affecting critical biological processes such as cellular metabolism and apoptosis (Asiedu2018Pathways). Additionally, TAF1L has been associated with vestibular schwannomas, where it is predicted to have damaging or oncogenic mutations (Fujita2023Genetic). These findings highlight the clinical significance of TAF1L in various cancers, underscoring its potential as a biomarker for diagnosis and treatment.

## Interactions
TAF1L, a gene encoding a protein similar to TAF1, is involved in several key interactions that facilitate transcriptional regulation. TAF1L can directly interact with the TATA-binding protein (TBP), a crucial component of the transcription factor TFIID complex. This interaction is similar to that of TAF II 250, suggesting that TAF1L can substitute for TAF II 250 during male meiosis when the X chromosome, where TAF II 250 is located, is transcriptionally silenced (Wang2002Functional). 

In addition to its role in transcription, TAF1L is involved in interactions with bromodomains. Studies have shown that TAF1L can be inhibited by benzoisoquinolinediones, which are selective inhibitors of bromodomains. These inhibitors, such as compound 5, have been shown to block interactions between TAF1L BD2 and histones H4 and H3.3, indicating a role for TAF1L in chromatin interactions (Bouché2017Benzoisoquinolinediones). The development of these inhibitors highlights the potential of TAF1L as a target for studying bromodomain interactions and their implications in various diseases (Bouché2017Benzoisoquinolinediones).


## References


[1. (Fujita2023Genetic) Takeshi Fujita, Kazuko Sakai, Natsumi Uehara, Yujiro Hoshi, Anjin Mori, Hajime Koyama, Mitsuo Sato, Kazuya Saito, Yasuhiro Osaki, Kazuto Nishio, and Katsumi Doi. Genetic variants of cancer‑associated genes analyzed using next‑generation sequencing in small sporadic vestibular schwannomas. Oncology Letters, February 2023. URL: http://dx.doi.org/10.3892/ol.2023.13707, doi:10.3892/ol.2023.13707. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/ol.2023.13707)

[2. (Asiedu2018Pathways) Michael K. Asiedu, Charles F. Thomas, Jie Dong, Sandra C. Schulte, Prasidda Khadka, Zhifu Sun, Farhad Kosari, Jin Jen, Julian Molina, George Vasmatzis, Ray Kuang, Marie Christine Aubry, Ping Yang, and Dennis A. Wigle. Pathways impacted by genomic alterations in pulmonary carcinoid tumors. Clinical Cancer Research, 24(7):1691–1704, April 2018. URL: http://dx.doi.org/10.1158/1078-0432.CCR-17-0252, doi:10.1158/1078-0432.ccr-17-0252. This article has 63 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1158/1078-0432.CCR-17-0252)

[3. (Wang2020TAF1L) Daiwei Wang, Hong Qi, Haoxing Zhang, Wei Zhou, Yanpeng Li, Ang Li, Qiong Liu, and Yun Wang. Taf1l promotes development of oral squamous cell carcinoma via decreasing autophagy-dependent apoptosis. International Journal of Biological Sciences, 16(7):1180–1193, 2020. URL: http://dx.doi.org/10.7150/ijbs.41148, doi:10.7150/ijbs.41148. This article has 12 citations and is from a peer-reviewed journal.](https://doi.org/10.7150/ijbs.41148)

[4. (Oh2016Frameshift) Hye Rim Oh, Chang Hyeok An, Nam Jin Yoo, and Sug Hyung Lee. Frameshift mutations in the mononucleotide repeats of taf1 and taf1l genes in gastric and colorectal cancers with regional heterogeneity. Pathology &amp; Oncology Research, 23(1):125–130, August 2016. URL: http://dx.doi.org/10.1007/s12253-016-0107-0, doi:10.1007/s12253-016-0107-0. This article has 29 citations.](https://doi.org/10.1007/s12253-016-0107-0)

[5. (Wang2002Functional) P. J. Wang. Functional substitution for tafii250 by a retroposed homolog that is expressed in human spermatogenesis. Human Molecular Genetics, 11(19):2341–2346, September 2002. URL: http://dx.doi.org/10.1093/hmg/11.19.2341, doi:10.1093/hmg/11.19.2341. This article has 71 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/11.19.2341)

[6. (WhiteCooper2011Unique) H. White-Cooper and I. Davidson. Unique aspects of transcription regulation in male germ cells. Cold Spring Harbor Perspectives in Biology, 3(7):a002626–a002626, May 2011. URL: http://dx.doi.org/10.1101/cshperspect.a002626, doi:10.1101/cshperspect.a002626. This article has 36 citations and is from a peer-reviewed journal.](https://doi.org/10.1101/cshperspect.a002626)

[7. (Bouché2017Benzoisoquinolinediones) Léa Bouché, Clara D. Christ, Stephan Siegel, Amaury E. Fernández-Montalván, Simon J. Holton, Oleg Fedorov, Antonius ter Laak, Tatsuo Sugawara, Detlef Stöckigt, Cynthia Tallant, James Bennett, Octovia Monteiro, Laura Díaz-Sáez, Paulina Siejka, Julia Meier, Vera Pütter, Jörg Weiske, Susanne Müller, Kilian V. M. Huber, Ingo V. Hartung, and Bernard Haendler. Benzoisoquinolinediones as potent and selective inhibitors of brpf2 and taf1/taf1l bromodomains. Journal of Medicinal Chemistry, 60(9):4002–4022, May 2017. URL: http://dx.doi.org/10.1021/acs.jmedchem.7b00306, doi:10.1021/acs.jmedchem.7b00306. This article has 49 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1021/acs.jmedchem.7b00306)